Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 9;22(1):443.
doi: 10.1186/s12879-022-07377-4.

At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers

Devon P Humphreys  1 , Kathleen M Gavin  1   2 , Kaylan M Olds  1 , Marc P Bonaca  2   3 , Timothy A Bauer  4   5
Affiliations

At-home sample collection is an effective strategy for diagnosis and management of symptomatic and asymptomatic SARS-CoV-2 carriers

Devon P Humphreys et al. BMC Infect Dis. .

Abstract

Background: Diagnostic testing accessibility and asymptomatic transmission of SARS-CoV-2 present major challenges for curbing and preventing community prevalence of COVID-19. At-home sample collection for molecular testing provides a convenient and effective solution for disease containment and prevention.

Methods: This is a retrospective, cross-sectional, case-control study. Our primary aim was to determine the prevalence and relative risk of SARS-CoV-2 among asymptomatic versus symptomatic individuals using at-home sample collection kits for diagnosis. Participants included adults from across the United States who completed a COVID-19 Home Collection kit between May 2020 and September 2021. Main measurements included self-reported symptoms and at-home self-collected anterior nasal swab RT-PCR test results for SARS-CoV-2.

Results: Data from 282,831 individuals were included in this analysis. The overall SARS-CoV-2 prevalence of at-home test takers was low compared to national averages during this period (3.28% vs. 7.68%). Those reporting no symptoms were at lower risk of positive test results compared to those with symptoms (risk ratio: 0.080, 95% CI, 0.078-0.082). However, of all positive SARS-CoV-2 tests, 48.75% were from individuals reporting no symptoms at the time of testing.

Conclusions: We conclude that at-home sample collection is a viable option and potentially important strategy for improving access to testing, detecting asymptomatic cases, and curbing preventable transmission of COVID-19.

Keywords: Adults; COVID-19; Diagnosis; Humans; Prevalence; Risk; SARS-CoV-2; Specimen handling.

PubMed Disclaimer

Conflict of interest statement

Devon Humphreys, Kathleen Gavin, Kaylan Olds, and Timothy Bauer are full time employees of Everly Health, Inc. Dr. Bonaca is the Executive Director of CPC, a non-profit academic research organization affiliated with the University of Colorado, that receives research grant/consulting funding from: Abbott, Agios, Alexion Pharma, Alnylam, Amgen, Angionetics, ARCA Biopharma, Array, AstraZeneca, Atentiv, Audentes, Bayer, Better Therapeutics, Brigham and Women’s Hospital, Bristol-Myers Squibb, Cardiol Therapeutics, CellResearch, Cook Medical, Cook, CSL Behring, Eidos Therapeutics, EP Trading Co, Esperion Therapeutics, EverlyWell, Faraday, Fortress Biotech, HDL Therapeutics, Heartflow, Hummingbird Bioscience, Insmed, Janssen, Kowa Research, Lexicon, Merck, Medtronic, Moderna, Novate Medical, NovoNordisk, Pfizer, PhaseBio, PPD Development, Prairie Education and Research, Prothena Biosciences, Regeneron, Regio Biosciences, Sanifit Therapeutics, Sanofi, Smith and Nephew, Stealth BioTherapeutics, University of Colorado, Worldwide Clinical Trials, Wraser, Yale Cardiovascular Research Group. Dr. Bonaca also reports stock in Medtronic and Pfizer and consulting fees from Audentes.

Figures

Fig. 1
Fig. 1
Percent distribution of the study population by state
Fig. 2
Fig. 2
Risk of SARS-CoV-2 positivity in those reporting no symptoms relative to those that reported symptoms. The overall log risk ratio of a positive case given no symptoms to infection with symptoms is − 2.52 (0.080 on a non-log scale). We present these data on a log scale to visualize the relationships among each subcategory more clearly. Error bars are 95% confidence intervals, computed using Wald’s normal approximation and log-transformation
Fig. 3
Fig. 3
Distributions of Ct values from RT-PCR testing for detection of SARS-CoV-2, stratified by self-reported symptoms. Summary statistics including each distribution’s minimum Ct value, median, maximum, mean, standard deviation (SD), and skewness are presented by status at the top of the figure. Results here are presented for the N1 gene only. Bin widths were set to 0.5 Ct units. N = 7571 positive tests for which Ct values were available from a single partner laboratory, including repeat tests for the same individual within a 90-day window and new infections outside of a 90-day window since the first positive result
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54. doi: 10.1038/s41579-020-00459-7. - DOI - PMC - PubMed
    1. Tadj A, Sidi Mohammed Lahbib S. Our overall current knowledge of COVID 19: an overview. Microbes Infect Chemother. 2021;1:e1262. doi: 10.54034/mic.e1262. - DOI
    1. Somerville M, Curran JA, Dol J, Boulos L, Saxinger L, Doroshenko A, et al. Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. BMJ Open. 2021;11(12):e055781. doi: 10.1136/bmjopen-2021-055781. - DOI - PMC - PubMed
    1. Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, et al. COVID-19 vaccine—long term immune decline and breakthrough infections. Vaccine. 2021;39(48):6984–9. doi: 10.1016/j.vaccine.2021.10.038. - DOI - PMC - PubMed
    1. Team CC-VBCI. COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792–3. doi: 10.15585/mmwr.mm7021e3. - DOI - PMC - PubMed